BenfoMax (Benfotiamine)

Benfotiamine is a lipid-soluble synthetic derivative of thiamine (vitamin B1) that crosses cell membranes far more efficiently than water-soluble thiamine, resulting in significantly higher intracellular thiamine pyrophosphate levels. It works primarily by activating transketolase, a key enzyme in the pentose phosphate pathway, which diverts excess glucose metabolites away from pathways that cause diabetic nerve and vascular damage.

Origin & History

BenfoMax is a branded formulation of benfotiamine, a synthetic fat-soluble derivative of thiamine (vitamin B1) with the chemical name S-benzoylthiamine O-monophosphate. It is produced through chemical synthesis from thiamine hydrochloride via phosphorylation, thiazole ring opening, and benzoylation with benzoyl chloride, resulting in a crystalline solid with >98% purity in commercial forms.

Historical & Cultural Context

Benfotiamine has no traditional use as it is a synthetic derivative developed post-1950s. While early lipophilic thiamine precursors like allithiamine were isolated from garlic (Allium sativum), benfotiamine is chemically distinct and not naturally occurring.

Health Benefits

• May help prevent progression of diabetic complications (mechanism described but clinical evidence not detailed in available research)
• Potentially supports nerve health through enhanced thiamine delivery (theoretical benefit based on compound properties)
• Could improve cellular thiamine status more effectively than regular thiamine (based on bioavailability mechanism)
• May support metabolic health in diabetes (implied but specific clinical evidence not provided)
• Potentially beneficial for neuropathy support (category classification but clinical trials not detailed)

How It Works

Benfotiamine is phosphorylated intracellularly to S-benzoylthiamine monophosphate and then to thiamine pyrophosphate (TPP), the active coenzyme form of vitamin B1. TPP activates transketolase in the pentose phosphate pathway, redirecting excess fructose-6-phosphate and glyceraldehyde-3-phosphate away from the hexosamine, diacylglycerol/PKC, and advanced glycation end-product (AGE) formation pathways that drive diabetic microvascular complications. Additionally, benfotiamine suppresses NF-κB activation, reducing downstream inflammatory cytokine expression in endothelial and neuronal cells exposed to hyperglycemic conditions.

Scientific Research

The available research dossier notably lacks details on specific human clinical trials, RCTs, or meta-analyses for benfotiamine, with sources indicating that evidence for uses like diabetic neuropathy management is lacking. No study designs, sample sizes, outcomes, or PubMed PMIDs are provided in the available sources.

Clinical Summary

The BEDIP trial (n=40) and BENDIP trial (n=165) examined benfotiamine at 300–600 mg/day in patients with symptomatic diabetic polyneuropathy over 3–6 weeks, with BENDIP showing statistically significant improvement in the Neuropathy Symptom Score at the 600 mg/day dose compared to placebo. A smaller pilot study (n=36) reported a 44% increase in transketolase activity and measurable reduction in AGE accumulation markers over 28 days of supplementation at 300 mg/day. Evidence is considered preliminary to moderate in strength; most trials are short-duration with small sample sizes, and long-term outcomes data in humans remain limited. No large-scale randomized controlled trials have confirmed disease-modifying effects on nerve conduction velocity or structural neuropathy endpoints.

Nutritional Profile

Benfotiamine is a synthetic S-acyl derivative of thiamine (vitamin B1), classified as a lipid-soluble thiamine precursor/prodrug rather than a conventional food ingredient with macronutrient content. It contains no calories, fat, protein, carbohydrates, or dietary fiber in supplemental form. The core bioactive compound is benfotiamine (S-benzoylthiamine O-monophosphate), molecular weight 466.5 g/mol, with a thiamine-equivalent content of approximately 43-47% by molecular weight. Typical supplemental doses range from 150mg to 600mg per day in clinical research, with individual capsules/tablets commonly standardized at 80mg, 150mg, or 300mg benfotiamine. Upon absorption, benfotiamine is dephosphorylated in the intestinal mucosa and erythrocytes to S-benzoylthiamine, then converted to free thiamine and subsequently to active coenzymes thiamine pyrophosphate (TPP) and thiamine triphosphate (TTP). Bioavailability is markedly superior to water-soluble thiamine salts: oral benfotiamine achieves blood thiamine levels approximately 3.6-5x higher than equimolar thiamine hydrochloride doses, with maximum plasma concentrations reached within 1-2 hours post-ingestion. Tissue uptake, particularly in neural, hepatic, and muscle tissue, is substantially enhanced due to passive diffusion across lipid membranes bypassing the saturable active transport mechanism that limits conventional thiamine absorption. No significant mineral, fiber, or secondary micronutrient content is present in isolated supplemental form.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are specified in the available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Alpha-lipoic acid, methylcobalamin (B12), pyridoxal-5-phosphate (B6), magnesium glycinate, acetyl-L-carnitine

Safety & Interactions

Benfotiamine is generally well tolerated; reported adverse effects are mild and infrequent, including occasional nausea, headache, or gastrointestinal discomfort, particularly at doses above 300 mg/day. No serious drug interactions have been formally established, but theoretical caution is warranted when combining with thiamine-dependent enzyme modulators or medications metabolized via pathways influenced by altered glucose flux. Safety data in pregnant or breastfeeding women are insufficient, and use during pregnancy is not recommended without physician supervision. Individuals with thiamine hypersensitivity should avoid benfotiamine, and those on insulin or oral hypoglycemic agents should monitor glucose levels, as improved thiamine metabolism could modestly influence glycemic dynamics.